BTAI Valuation

BioXcel Therapeutics Inc

Add to Watchlist

Advanced Chart

4.050

-0.05(-1.220%)1D

Overview
Forecast
Valuation
Earnings

BTAI Relative Valuation

BTAI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BTAI is overvalued; if below, it's undervalued.

Historical Valuation

BioXcel Therapeutics Inc (BTAI) is now in the Fair zone, suggesting that its current forward PS ratio of 56.96 is considered Fairly compared with the five-year average of -3.57. The fair price of BioXcel Therapeutics Inc (BTAI) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：4.05

Fair

-1.31

Trailing

Forward

-2.81

EV/EBITDA

BioXcel Therapeutics Inc. (BTAI) has a current EV/EBITDA of -2.81. The 5-year average EV/EBITDA is -2.99. The thresholds are as follows: Strongly Undervalued below -8.60, Undervalued between -8.60 and -5.80, Fairly Valued between -0.19 and -5.80, Overvalued between -0.19 and 2.61, and Strongly Overvalued above 2.61. The current Forward EV/EBITDA of -2.81 falls within the Historic Trend Line -Fairly Valued range.

-3.44

EV/EBIT

BioXcel Therapeutics Inc. (BTAI) has a current EV/EBIT of -3.44. The 5-year average EV/EBIT is -2.91. The thresholds are as follows: Strongly Undervalued below -8.49, Undervalued between -8.49 and -5.70, Fairly Valued between -0.13 and -5.70, Overvalued between -0.13 and 2.66, and Strongly Overvalued above 2.66. The current Forward EV/EBIT of -3.44 falls within the Historic Trend Line -Fairly Valued range.

56.96

BioXcel Therapeutics Inc. (BTAI) has a current PS of 56.96. The 5-year average PS is 70.41. The thresholds are as follows: Strongly Undervalued below -185.60, Undervalued between -185.60 and -57.59, Fairly Valued between 198.41 and -57.59, Overvalued between 198.41 and 326.41, and Strongly Overvalued above 326.41. The current Forward PS of 56.96 falls within the Historic Trend Line -Fairly Valued range.

-1.01

P/OCF

BioXcel Therapeutics Inc. (BTAI) has a current P/OCF of -1.01. The 5-year average P/OCF is -3.83. The thresholds are as follows: Strongly Undervalued below -12.12, Undervalued between -12.12 and -7.98, Fairly Valued between 0.31 and -7.98, Overvalued between 0.31 and 4.46, and Strongly Overvalued above 4.46. The current Forward P/OCF of -1.01 falls within the Historic Trend Line -Fairly Valued range.

-1.02

P/FCF

BioXcel Therapeutics Inc. (BTAI) has a current P/FCF of -1.02. The 5-year average P/FCF is -3.87. The thresholds are as follows: Strongly Undervalued below -11.82, Undervalued between -11.82 and -7.84, Fairly Valued between 0.10 and -7.84, Overvalued between 0.10 and 4.07, and Strongly Overvalued above 4.07. The current Forward P/FCF of -1.02 falls within the Historic Trend Line -Fairly Valued range.

BioXcel Therapeutics Inc (BTAI) has a current Price-to-Book (P/B) ratio of -0.25. Compared to its 3-year average P/B ratio of 4.30 , the current P/B ratio is approximately -105.79% higher. Relative to its 5-year average P/B ratio of 4.23, the current P/B ratio is about -105.88% higher. BioXcel Therapeutics Inc (BTAI) has a Forward Free Cash Flow (FCF) yield of approximately -94.59%. Compared to its 3-year average FCF yield of -263.99%, the current FCF yield is approximately -64.17% lower. Relative to its 5-year average FCF yield of -162.62% , the current FCF yield is about -41.83% lower.

-0.25

P/B

Median3y

4.30

Median5y

4.23

-94.59

FCF Yield

Median3y

-263.99

Median5y

-162.62

Competitors Valuation Multiple

The average P/S ratio for BTAI's competitors is 24.42, providing a benchmark for relative valuation. BioXcel Therapeutics Inc Corp (BTAI) exhibits a P/S ratio of 56.96, which is 133.27% above the industry average. Given its robust revenue growth of -89.13%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BTAI.O

BioXcel Therapeutics Inc

Precision BioSciences Inc

Incannex Healthcare Inc

76.48

19.40M

ALXO.O

ALX Oncology Holdings Inc

Loss

62.65M

Performance Decomposition

Market capitalization of BTAI decreased by 56.73% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -751.72 to -15.99K.

The secondary factor is the Revenue Growth, contributed -89.13%to the performance.

Overall, the performance of BTAI in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-89.13%

1.10M → 120.00K

Revenue Growth

2027.01%

-751.72 → -15.99K

Margin Expansion

-1994.61%

0.02 → -0.37

P/E Change

-56.73%